- TRADE NAME: Parsabiv (Amgen)
- INDICATIONS: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis
- CLASS: Calcimimetic
- HALF-LIFE: 3–4 days
- FDA APPROVAL DATE: 02/07/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No data available
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
